Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group LtdfiledCriticalGlaxo Group Ltd
Publication of PE20001021A1publicationCriticalpatent/PE20001021A1/es
Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
Compuesto ligando de integrina, uso del elemento estrutural-g-l para prepararlo, droga que contiene a este ultimo, preparacion farmaceutica que comprende a dicho compuesto y uso para la produccion de drogas.
A Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: RTOG PA0411